Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
Identifieur interne : 001304 ( Main/Exploration ); précédent : 001303; suivant : 001305Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
Auteurs : Pierre Tiberghien [France] ; Xavier De Lamballerie [France] ; Pascal Morel [France] ; Pierre Gallian [France] ; Karine Lacombe [France] ; Yazdan Yazdanpanah [France]Source :
- Vox sanguinis [ 1423-0410 ] ; 2020.
Abstract
Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.
DOI: 10.1111/vox.12926
PubMed: 32240545
Affiliations:
- France
- Bourgogne-Franche-Comté, Franche-Comté, Provence-Alpes-Côte d'Azur, Île-de-France
- Besançon, Marseille, Paris
- Université de Franche-Comté
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?</title><author><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name><affiliation wicri:level="1"><nlm:affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, La Plaine-St Denis</wicri:regionArea><wicri:noRegion>La Plaine-St Denis</wicri:noRegion><wicri:noRegion>La Plaine-St Denis</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName><orgName type="university">Université de Franche-Comté</orgName></affiliation></author><author><name sortKey="De Lamballerie, Xavier" sort="De Lamballerie, Xavier" uniqKey="De Lamballerie X" first="Xavier" last="De Lamballerie">Xavier De Lamballerie</name><affiliation wicri:level="3"><nlm:affiliation>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Morel, Pascal" sort="Morel, Pascal" uniqKey="Morel P" first="Pascal" last="Morel">Pascal Morel</name><affiliation wicri:level="1"><nlm:affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, La Plaine-St Denis</wicri:regionArea><wicri:noRegion>La Plaine-St Denis</wicri:noRegion><wicri:noRegion>La Plaine-St Denis</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName><orgName type="university">Université de Franche-Comté</orgName></affiliation></author><author><name sortKey="Gallian, Pierre" sort="Gallian, Pierre" uniqKey="Gallian P" first="Pierre" last="Gallian">Pierre Gallian</name><affiliation wicri:level="1"><nlm:affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, La Plaine-St Denis</wicri:regionArea><wicri:noRegion>La Plaine-St Denis</wicri:noRegion><wicri:noRegion>La Plaine-St Denis</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lacombe, Karine" sort="Lacombe, Karine" uniqKey="Lacombe K" first="Karine" last="Lacombe">Karine Lacombe</name><affiliation wicri:level="3"><nlm:affiliation>Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>REACTing Inserm, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>REACTing Inserm, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>AP-HP Hôpital Bichat, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP Hôpital Bichat, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32240545</idno><idno type="pmid">32240545</idno><idno type="doi">10.1111/vox.12926</idno><idno type="wicri:Area/Main/Corpus">001817</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001817</idno><idno type="wicri:Area/Main/Curation">001817</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001817</idno><idno type="wicri:Area/Main/Exploration">001817</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?</title><author><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name><affiliation wicri:level="1"><nlm:affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, La Plaine-St Denis</wicri:regionArea><wicri:noRegion>La Plaine-St Denis</wicri:noRegion><wicri:noRegion>La Plaine-St Denis</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName><orgName type="university">Université de Franche-Comté</orgName></affiliation></author><author><name sortKey="De Lamballerie, Xavier" sort="De Lamballerie, Xavier" uniqKey="De Lamballerie X" first="Xavier" last="De Lamballerie">Xavier De Lamballerie</name><affiliation wicri:level="3"><nlm:affiliation>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Morel, Pascal" sort="Morel, Pascal" uniqKey="Morel P" first="Pascal" last="Morel">Pascal Morel</name><affiliation wicri:level="1"><nlm:affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, La Plaine-St Denis</wicri:regionArea><wicri:noRegion>La Plaine-St Denis</wicri:noRegion><wicri:noRegion>La Plaine-St Denis</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Franche-Comté</region><settlement type="city">Besançon</settlement></placeName><orgName type="university">Université de Franche-Comté</orgName></affiliation></author><author><name sortKey="Gallian, Pierre" sort="Gallian, Pierre" uniqKey="Gallian P" first="Pierre" last="Gallian">Pierre Gallian</name><affiliation wicri:level="1"><nlm:affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Etablissement Français du Sang, La Plaine-St Denis</wicri:regionArea><wicri:noRegion>La Plaine-St Denis</wicri:noRegion><wicri:noRegion>La Plaine-St Denis</wicri:noRegion></affiliation><affiliation wicri:level="3"><nlm:affiliation>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Lacombe, Karine" sort="Lacombe, Karine" uniqKey="Lacombe K" first="Karine" last="Lacombe">Karine Lacombe</name><affiliation wicri:level="3"><nlm:affiliation>Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>REACTing Inserm, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>REACTing Inserm, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>AP-HP Hôpital Bichat, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>AP-HP Hôpital Bichat, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Vox sanguinis</title><idno type="eISSN">1423-0410</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32240545</PMID><DateRevised><Year>2020</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0410</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Vox sanguinis</Title><ISOAbbreviation>Vox Sang.</ISOAbbreviation></Journal><ArticleTitle>Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/vox.12926</ELocationID><Abstract><AbstractText>Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.</AbstractText><CopyrightInformation>© 2020 International Society of Blood Transfusion.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9310-8322</Identifier><AffiliationInfo><Affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morel</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallian</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Etablissement Français du Sang, La Plaine-St Denis, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IHU Méditerranée Infection, Unité des Virus Émergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacombe</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sorbonne Université Inserm IPLESP Hôpital St Antoine AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdanpanah</LastName><ForeName>Yazdan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>REACTing Inserm, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>AP-HP Hôpital Bichat, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vox Sang</MedlineTA><NlmUniqueID>0413606</NlmUniqueID><ISSNLinking>0042-9007</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">infectious disease</Keyword><Keyword MajorTopicYN="N">plasma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32240545</ArticleId><ArticleId IdType="doi">10.1111/vox.12926</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Lu R, Zhao X, Li J, et al.: Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565-574.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2002032</Citation></Reference><Reference><Citation>https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. accessed 8/4/2020.</Citation></Reference><Reference><Citation>Fauci AS, Lane HC, Redfield RR: Covid-19 - Navigating the Uncharted. N Engl J Med 2020; 382:1268-1269</Citation></Reference><Reference><Citation>Chen L, Xiong J, Bao L, et al.: Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20:398-400</Citation></Reference><Reference><Citation>Casadevall A, Pirofski LA: The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130:1545-1548</Citation></Reference><Reference><Citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al.: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80-90</Citation></Reference><Reference><Citation>Luke TC, Kilbane EM, Jackson JL, et al.: Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609</Citation></Reference><Reference><Citation>Hung IF, To KK, Lee CK, et al.: Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-56</Citation></Reference><Reference><Citation>Cheng Y, Wong R, Soo YO, et al.: Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-6</Citation></Reference><Reference><Citation>Hung IFN, To KKW, Lee CK, et al.: Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144:464-473</Citation></Reference><Reference><Citation>Walls AC, Park YJ, Tortorici MA, et al.: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020. pii: S0092-8674(20)30262-2</Citation></Reference><Reference><Citation>Zhang JS, Chen JT, Liu YX, et al.: A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005; 77:147-150</Citation></Reference><Reference><Citation>Woelfel R, Comran VM, Guggemos W, et al. :Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv 2020. 03.05.20030502 (not peer-reviewed yet)</Citation></Reference><Reference><Citation>Subbarao K, McAuliffe J, Vogel L, et al.: Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78:3572-3577</Citation></Reference><Reference><Citation>Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv 2020. https://doi.org/10.1101/2020.03.13.990226(not yet peer-reviewed).</Citation></Reference><Reference><Citation>Soo YO, Cheng Y, Wong R, et al.: Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-8</Citation></Reference><Reference><Citation>Shen C, Wang Z, Zhao F, et al.: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020. doi:10.1001/jama.2020.4783</Citation></Reference><Reference><Citation>Duan K, Liu B, Li C, et al.: Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A.2020. pii:.202004168</Citation></Reference><Reference><Citation>van Griensven J, Edwards T, de Lamballerie X, et al.: Evaluation of convalescent plasma for ebola virus disease in Guinea. N Engl J Med 2016; 374:33-42</Citation></Reference><Reference><Citation>Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, et al.: Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015; 3:554-62</Citation></Reference><Reference><Citation>Chun S, Chung CR, Ha YE, et al.: Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome. Ann Lab Med 2016; 36:393-5</Citation></Reference><Reference><Citation>Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019;4: pii: 123158</Citation></Reference><Reference><Citation>Smatti MK, Al Thani AA, Yassine HM: Viral-induced enhanced disease illness. Front Microbiol 2018; 5:2991</Citation></Reference><Reference><Citation>Houser KV, Broadbent AJ, Gretebeck L, et al.: Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog 2017; 13:e1006565</Citation></Reference><Reference><Citation>Taylor A, Foo SS, Bruzzone R, et al.: Fc receptors in antibody-dependent enhancement of viral infections. Immunol Rev 2015; 268:340-64</Citation></Reference><Reference><Citation>Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al.: Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7:e35421</Citation></Reference><Reference><Citation>Peiris JS, Lai ST, Poon LL, et al.: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319-1325</Citation></Reference><Reference><Citation>Wang SF, Tseng SP, Yen CH, et al.: Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014; 451:208-14</Citation></Reference><Reference><Citation>Wang Q, Zhang L, Kuwahara K, et al.: Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis 2016; 2:361-76</Citation></Reference><Reference><Citation>Zhang L, Zhang F, Yu W, et al.: Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol 2006; 78:1-8</Citation></Reference><Reference><Citation>Li T, Xie J, He Y, et al.: Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS One 2006; 1:e24</Citation></Reference><Reference><Citation>Xie L, Liu Y, Fan B, et al.: Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir Res 2005; 6:5</Citation></Reference><Reference><Citation>Cao WC, Liu W, Zhang PH, et al.: Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 2007; 357:1162-1163</Citation></Reference><Reference><Citation>Liu L, Xie J, Sun J, et al.: Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. Scand J Infect Dis 2011; 43:515-21</Citation></Reference><Reference><Citation>Hung IF, To KK, Lee CK, et al.: Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010; 51:274-279</Citation></Reference><Reference><Citation>Ko JH, Müller MA, Seok H, et al.: Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis 2017; 89:106-111</Citation></Reference><Reference><Citation>Zhao J, Yuan Q, Wang H, et al.: Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. pii: ciaa344.https://doi.org/10.1093/cid/ciaa344</Citation></Reference><Reference><Citation>Agence national de sécurité des médicaments et des produits de santé (ANSM). Principes et bonnes pratiques pour les établissements de transfusion sanguine et les dépôts de sang hospitaliers. Décision du 18/7/2018</Citation></Reference><Reference><Citation>Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2018; 15: 192. Erratum. In: Virol J. 2019;16:12</Citation></Reference><Reference><Citation>Wong HK, Lee CK, Hung IF, et al.: Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion 2010; 50:1967-1971</Citation></Reference><Reference><Citation>Hashem AM, Hassan AM, Tolah AM, et al.: Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med 2019; 29:434-441</Citation></Reference><Reference><Citation>Keil SD, Bowen R, Marschner S: Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion 2016; 56:2948-2952</Citation></Reference><Reference><Citation>Eickmann M, Gravemann U, Handke W, et al.: Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. Vox Sang. 2020. https://doi.org/10.1111/vox.12888</Citation></Reference><Reference><Citation>Geisen C, Kann G, Strecker T, et al.: Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies. Vox Sang 2016; 110:329-335</Citation></Reference><Reference><Citation>Dean CL, Hooper JW, Dye JM, et al.: Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion 2020. https://doi.org/10.1111/trf.15739</Citation></Reference><Reference><Citation>Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA 2020. https://doi.org/10.1001/jama.2020.2783. (Pubmed ahead of print)</Citation></Reference><Reference><Citation>Baden LR, Rubin EJ, Morrissey S, et al.: We can do better - improving outcomes in the midst of an emergency. N Engl J Med 2017; 377:1482-1484</Citation></Reference><Reference><Citation>Zhao J, Yang Y, Huang HP, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. medRxiv 2020. 03.11.20031096 (not peer-reviewed yet</Citation></Reference><Reference><Citation>https://europeanbloodalliance.eu/,accessed 20/3/2020.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Bourgogne-Franche-Comté</li><li>Franche-Comté</li><li>Provence-Alpes-Côte d'Azur</li><li>Île-de-France</li></region><settlement><li>Besançon</li><li>Marseille</li><li>Paris</li></settlement><orgName><li>Université de Franche-Comté</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name></noRegion><name sortKey="De Lamballerie, Xavier" sort="De Lamballerie, Xavier" uniqKey="De Lamballerie X" first="Xavier" last="De Lamballerie">Xavier De Lamballerie</name><name sortKey="Gallian, Pierre" sort="Gallian, Pierre" uniqKey="Gallian P" first="Pierre" last="Gallian">Pierre Gallian</name><name sortKey="Gallian, Pierre" sort="Gallian, Pierre" uniqKey="Gallian P" first="Pierre" last="Gallian">Pierre Gallian</name><name sortKey="Lacombe, Karine" sort="Lacombe, Karine" uniqKey="Lacombe K" first="Karine" last="Lacombe">Karine Lacombe</name><name sortKey="Morel, Pascal" sort="Morel, Pascal" uniqKey="Morel P" first="Pascal" last="Morel">Pascal Morel</name><name sortKey="Morel, Pascal" sort="Morel, Pascal" uniqKey="Morel P" first="Pascal" last="Morel">Pascal Morel</name><name sortKey="Tiberghien, Pierre" sort="Tiberghien, Pierre" uniqKey="Tiberghien P" first="Pierre" last="Tiberghien">Pierre Tiberghien</name><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001304 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001304 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32240545
|texte= Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32240545" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |